The long-term outcome of interferon- α treated and untreated patients with HBeAg-negative chronic hepatitis B

Background/Aims : This study aimed to evaluate the effect of interferon- α therapy on the long-term outcome of HBeAg-negative chronic hepatitis B. Methods : A cohort of 209 interferon- α treated and 195 untreated patients with histologically documented HBeAg-negative chronic hepatitis B were closely...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hepatology 2001-02, Vol.34 (2), p.306-313
Main Authors: Papatheodoridis, George V, Manesis, Emanuel, Hadziyannis, Stephanos J
Format: Article
Language:English
Subjects:
Adolescent
Adult
Age Factors
Aged
Biological and medical sciences
Carcinoma, Hepatocellular - etiology
Chronic hepatitis B
Cirrhosis
Cohort Studies
Decompensation
Disease-Free Survival
Female
HBeAg negative
Hepatitis B e Antigens - blood
Hepatitis B, Chronic - complications
Hepatitis B, Chronic - drug therapy
Hepatitis B, Chronic - mortality
Hepatitis B, Chronic - virology
Hepatocellular carcinoma
Humans
Immunomodulators
Interferon
Interferon Type I - therapeutic use
Liver Neoplasms - etiology
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Recombinant Proteins
Survival
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background/Aims : This study aimed to evaluate the effect of interferon- α therapy on the long-term outcome of HBeAg-negative chronic hepatitis B. Methods : A cohort of 209 interferon- α treated and 195 untreated patients with histologically documented HBeAg-negative chronic hepatitis B were closely followed for a mean of 6 (1–13.5) years. Patients with decompensated liver disease and/or hepatocellular carcinoma at presentation were excluded. Results : Survival and complication (liver decompensation and/or hepatocellular carcinoma) - free survival were significantly worse in patients with compared to those without baseline cirrhosis and in patients older compared to those younger than 45 years ( P
ISSN:0168-8278
1600-0641
DOI:10.1016/S0168-8278(00)00094-5